Filing Details
- Accession Number:
- 0001209191-23-056063
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-20 16:30:22
- Reporting Period:
- 2023-11-16
- Accepted Time:
- 2023-11-20 16:30:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1674930 | Fulgent Genetics Inc. | FLGT | Services-Medical Laboratories (8071) | 812621304 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1819718 | Jian Xie | C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731 | President And Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-11-16 | 1,617 | $27.25 | 386,903 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 220,816 | Indirect | By Trust |
Footnotes
- The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019.
- The shares were sold in multiple transactions at prices ranging from $27.02 to $27.54, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.